Gapping up
In reaction to earnings/guidance:
- XM +29.9%, STX +9.2%, MBLY +8.5%, TSLA +7.1%, LEVI +6.4%, CNX +4.8%, ETD +4.4%, URI +4.4% (also initiates dividend; also plans to restart its share repurchase program), STM +4.3%, LVS +3.9%, TSCO +3.8%, ROK +3.6%, NOK +3%, XRX +2.8%, BHLB +2.3%, HXL +2% (also increases dividend), AXS +2%, AAL +2%, XEL +1.7%, ADM +1.6%, CALX +1.3%, AIT +1.3%, AXTA +1.2%, NOC +1.1%, RLI +1%, LBRT +1%, NTCT +1%, PLUG +0.9%, STLD +0.8%, MUR +0.6%, VLO +0.6%, CNS +0.5%
Other news:
- ACIU +11.5% (ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer's Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial)
- DV +8.2% (to join S&P SmallCap 600)
- LTRX +4.5% (announces record $40 mln contract with Gridspertise)
- CVX +3.3% (authorizes new $75 bln share repurchase program; also increases dividend)
- ET +2.4% (increases dividend)
- BHLB +2.3% (names new CFO; also authorizes new $50 mln share repurchase program)
- NKLA +1.9% (introduces new hydrogen energy brand "HYLA")
Analyst comments:
- FGEN +3.5% (upgraded to Outperform from Mkt Perform at Raymond James)
